Extrawell Pharmaceutical (HKG:0858) has agreed to subscribe for RMB2.5 million of the registered capital of a target company, a wholly-owned subsidiary of United Gene High-Tech Group (HKG:0399), by way of capital injection. Upon the completion, the enlarged registered capital of the target company will be owned as to 20% by Extrawell and 80% by United Gene High-Tech.

The target company has set up a health-care centre in Shanghai and has commenced business since September 2011, providing high-end health care management services to the public with genome technology as its competitive edge, Extrawell says.

Mao yumin, the chairman and holder of 21% stake of Extrawell, is the honorary chairman and controlling shareholder of United Gene High-Tech interested in approximately 50.8% of the issued share capital of United Gene High-Tech.